A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection

Trial Profile

A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms APOSTLE
  • Most Recent Events

    • 01 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 17 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
    • 17 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top